Summary
Becton, Dickinson and Company (BD) has announced a significant strategic move, entering into a non-binding letter of intent to divest its Critical Care product line to AorTech International plc for approximately $52 million. This divestiture is part of BD's broader strategy to streamline its portfolio by divesting product lines with combined revenues under $200 million. The Critical Care unit generated approximately $47 million in sales for the fiscal year ended September 30, 2001. The transaction, expected to close in the second half of BD's fiscal year, will involve a substantial, largely non-cash special charge estimated between $25 million and $30 million. While this charge will impact reported earnings, the company anticipates a minimal dilution of less than one cent per diluted share for fiscal year 2002, excluding the special charge, assuming the divestiture was effective at the beginning of the fiscal year. Investors should note that the deal is subject to final agreement, and board and shareholder approvals.
Key Highlights
- 1BD entered into a non-binding letter of intent to sell its Critical Care product line to AorTech International plc.
- 2The potential sale price is approximately $52 million, subject to adjustments based on future sales.
- 3The Critical Care product line generated sales of approximately $47 million in fiscal year 2001.
- 4This divestiture aligns with BD's previously announced strategy to divest product lines with combined revenues under $200 million.
- 5The transaction is contingent upon the execution of a definitive agreement and necessary approvals from both companies' boards and AorTech's shareholders.
- 6BD expects to record a special charge, estimated at $25 million to $30 million (substantially non-cash), upon closing.
- 7The company anticipates a minimal impact (less than $0.01 per diluted share) on fiscal year 2002 earnings, excluding the special charge.